Tuesday, March 3, 2026

Datametrex Secures Rights To Sell And Distribute Rapid COVID-19 Antigen Test Kits

Datametrex AI (TSXV: DM) this morning announced that it has secured the rights to sell and distribute a rapid antigen detection kit from South Korean manufacturer PCL Inc. The main benefit of the test is that with 97% accuracy, they produce results in as little as 5 to 10 minutes with no extra equipment being required for the consumer.

Datametrex AI's Logo

The test hosts advantages over others on the market solely as a result of the rapid testing nature of the product, combined with the lack of additional equipment being needed to conduct the test. The test is a method of measuring the presence of a COVID-19 infection via an in-vitro diagnostic medical device. It detects antigen of the SARS-CoV-2 virus from a persons oropharyngeal and nasopharyngeal secretions. Like a simple pregnancy test, if antigens are found a colored line appears in the T line area.

It’s said that the test has a clinical sensitivity, i.e., the ability to confirm the actual positive of the approved person, of 100%, and the clinical specificity, i.e the ability to confirm the actual negative of the negative person, of 97.78%. The antigen test has been awarded numerous certifications, including CE, Korea FDA, UNGM and more. It’s also been approved by the EU, Qatar, United Arab Emirates, India, Russia, Ecuador, Guatemala and Colombia.

“According to the manufacturer, PCL, this test can detect antigens of COVID-19 from a swab in the nose or throat and provide results in 10 minutes with over 97% accuracy. These almost-instant kits can be easily used at home. With the rise of cases in the United States and throughout the world, we at Datametrex believes it is critical to test and protect.”

Marshall Gunter, CEO of Datametrex

The strong benefit of the instant antigen kits that require no additional equipment, is that they can be conducted at home easily, with nearly instant results. This eliminates excessive wait times as high as 3-5 days or more previously experienced by individuals that have had other forms of COVID-19 tests performed.

Datametrex AI last traded at $0.15 on the TSX Venture.


FULL DISCLOSURE: DataMetrex AI Limited is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DataMetrex AI Limited on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Is Gold Entering a New 15-Year Cycle? | Rob Husband

A 100,000 Ounce Per Year Gold Plan in Utah | Scott Trebilcock — Revival Gold

Can Australia Rival the Athabasca for Uranium? | Marnie Finlayson – DevEx Resources

Recommended

Silver47 Launches 7,000-Meter Hughes Drill Program In Nevada

Advanced Gold Acquires Nevada Property With Historic Production At 1,611 g/t Silver

Related News

Retail and Office Tenants Anticipate Increasing Costs, Reduced Revenue Due to Coronavirus

As a result of the coronavirus pandemic, the commercial real estate industry has been struggling...

Thursday, June 25, 2020, 02:45:00 PM

Relay Medical Enters Binding LOI For Global Rights To COVID-19 Tests

Relay Medical (CSE: RELA) has entered into an arrangement to exclusively sell and distribute two...

Tuesday, November 10, 2020, 07:12:32 AM

Datametrex Acquires Medi-Call For $12.0 Million In All-Stock Transaction

Datametrex AI (TSXV: DM) continues to expand its healthcare division. The firm this morning indicated...

Monday, June 21, 2021, 08:09:50 AM

Pantry Stockpiling Surges 3,400% As Second COVID-19 Wave Sets In

As the outlook for the coronavirus pandemic turns bleak across the US amid record-breaking surges...

Thursday, October 29, 2020, 10:35:36 AM

Coronavirus is Becoming 30% More Infectious After Mutated Strain Confirmed in Hong Kong

A new strain of the deadly coronavirus has been discovered in Hong Kong, and according...

Tuesday, July 14, 2020, 08:22:00 PM